Precision vs Imprecision Oncology (White Paper)
July 30, 2021
Precision vs Imprecision OncologyI got to thinking recently about the push towards developing drugs for molecularly stratified patientpopulations, including a spate of approvals over the past few years for agents targeting aberrantly expressed(mutated, translocated, amplified, etc.) proteins, as opposed to many of the blockbuster drugs (based on WWsales—see data above from EvaluatePharma) that are not “precision medicine” agents….More by clicking the Download pdf green button above.
Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice
Cello Health BioConsulting.